Eli Lilly, NIH grants, Novartis, Regeneron: Readout Newsletter
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter…
GLP-1s in children, Syntis Bio, Vera: Readout Newsletter
National Biotech Reporter Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways…
AI hunts new uses for Phase 3 metabolic drug
THPharm already has a drug in late-stage trials. Now it’s using AI to work backwards and find out…
Amylyx endocrine drug succeeds in key study for low blood sugar
Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected…
Enveda makes ‘exercise pill’ that skips the treadmill
Drug mimics a hormone you make when you push hard at the gym – early results suggest it…
Peptide Synthesis Could Speed Up Cancer Drug Production
No matter one’s career experience or level of industry expertise, working at a start-up company is not for…
Enveda weight loss maintenance pill mimics exercise in early tests
If you could design an oral treatment that limits appetite and mimics some effects of physical activity, you…
Eli Lilly to offer retatrutide access given earlier to just one patient
Lizzy leads STAT’s coverage of the FDA. Her stories explore the relationship between politics and science at the…
Compounded GLP-1s: Why doctors worry and the FDA is cracking down
So, are these copycat versions of the weight loss drugs safe? Poison control centers across the U.S. have…
China, Shanghai, AI hair growth drug, Eli Lilly: Readout Newsletter
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter…
Definium LSD therapy for major depression helped patients in Phase 3 trial
Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected…
Industry and regulators signal a smarter, collaborative era for supplement oversight
While the industry has spent years bracing for and fending off a heavier regulatory hand, what it heard…